Trial Profile
Immunogenicity and Safety of GSK Biologicals' Meningococcal Vaccine (GSK 134612) When Co-administered With a Pneumococcal Conjugate Vaccine and Infanrix Hexa in Healthy Infants
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa); Meningococcal vaccine group C conjugate; Pneumococcal 10-valent vaccine conjugate
- Indications Meningococcal infections
- Focus Pharmacodynamics; Registrational
- Acronyms MenACWY-TT-083
- Sponsors GlaxoSmithKline; GSK
- 31 Mar 2018 Results published in the Pediatric Infectious Disease Journal
- 19 Dec 2016 Primary end point (Immunogenicity of 2 MenACWY-TT doses) has been met.
- 19 Dec 2016 Primary end point (Non-inferiority of 2 MenACWY-TT doses vs 2 MenC-TT doses) has been met.